Price
$75.35+12.23%Social Signal Score
Analyst Ratings
26 analystsRevenue
$2.82B+58.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David J. Endicott
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 25,000
- Beta
- 0.70
- Country
- CH
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.54
Financials
Revenue
$2.82B+58.3%Net Income
$0.00-100.0%EBITDA
$270.00M-8.5%Free Cash Flow
$414.00M+58.6%EPS (diluted)
$0.00-100.0%Shares Outstanding (diluted)
488.70M+0.0%Operating Expenses
$1.63BCash & Debt
$1.46BReturn of Capital
$463.00MDividend per Share
$0.36Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.40B | $980.00M | $1.99 |
| 2024 | $9.91B | $1.02B | $2.06 |
| 2023 | $9.46B | $974.00M | $1.98 |
| 2022 | $8.72B | $335.00M | $0.68 |
| 2021 | $8.29B | $376.00M | $0.77 |
| 2020 | $6.83B | $-531.00M | $-1.09 |
| 2019 | $7.51B | $-656.00M | $-1.34 |
| 2018 | $7.15B | $-227.00M | $-0.46 |
| 2017 | $6.79B | $256.00M | $0.52 |
| 2016 | $6.60B | $-170.00M | $-0.35 |
| 2015 | $6.52B | $296.27M | $0.61 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALC's reported EPS growth of 12.6% a year over 10 years.
- EPS in 5 years
- $3.58
- Implied price
- $143.36
- Return from $64.23
- 17.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $71.27 — today's price is already 9.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| 2.6% | -0.4% | 3.6% | 7.0% | 10.0% | 12.8% |
| 7.6% | 4.5% | 8.6% | 12.2% | 15.4% | 18.2% |
| 12.6% | 9.3% | 13.7% | 17.4% | 20.7% | 23.7% |
| 17.6% | 14.2% | 18.7% | 22.6% | 26.1% | 29.2% |
| 22.6% | 19.0% | 23.8% | 27.8% | 31.5% | 34.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-68.09%Social Signal Score
Mentions (10)
- Newszacks.com·32d ago·Neutral
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now? Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Alcon: A Re-Rating In Eyesight Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting mid-teens EPS growth but pricing in neither margin expansion nor pipeline optionality. Management targets 25% core operating margin by FY2027E, with current core EPS guidance raised to +12–15% growth and significant capital returns underway.
View source ↗ - Newsbusinesswire.com·40d ago·Neutral
Alcon Prices EUR 500 Million Senior Notes Offering GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
View source ↗ - Newsseekingalpha.com·50d ago·Positive
Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second consecutive quarter. My DCF valuation states the stock is undervalued by 5.52%. I rate ALC a buy.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript Alcon Inc. (ALC) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·55d ago·Positive
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.
View source ↗ - Newsreuters.com·56d ago·Negative
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate Swiss-American eye care company Alcon on Monday hiked its profit guidance and lowered its estimate for the full-year tariff impact to $40 million to $90 million, factoring in an anticipated refund of around $60 million from the U.S. government.
View source ↗ - Newszacks.com·56d ago·Neutral
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsbusinesswire.com·56d ago·Positive
New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth GENEVA--(BUSINESS WIRE)--New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth.
View source ↗ - Newsbenzinga.com·57d ago·Neutral
Aecom, Alcon And 3 Stocks To Watch Heading Into Monday With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $0.89 per share
Typical surprise +2.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$0.84 vs $0.77beat
- Tue, May 5$0.85 vs $0.80beat
- Tue, Feb 24$0.78 vs $0.79miss
- Tue, Nov 11$0.79 vs $0.77beat
- Tue, Aug 19$0.76 vs $0.71beat
- Tue, May 13$0.73 vs $0.76miss
Estimates and results for ALC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 2, 2026 (28d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 9, 2026 (28d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Apr 15, 2025 (43d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (19d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (28d later)Buy$1,001 - $15,000
- Peter Meijerhouse · MI03 · disclosed Mar 16, 2021 (27d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2020 (36d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2020 (37d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Jun 25, 2020 (20d later)Buy$100,001 - $250,000
- Debbie Dingellhouse · MI12 · disclosed Nov 15, 2019 (14d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Apr 28, 2019 (13d later)Sell$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Apr 28, 2019 (13d later)Sell$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Apr 28, 2019 (13d later)Sell$1,001 - $15,000
- Debbie Dingellhouse · MI12 · disclosed Apr 18, 2019 (7d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.